Bropirimine is a synthetic agonist of toll-like receptor 7 (TLR7). Bropirimine inhibits the differentiation of osteoclast precursor cells into osteoclasts through TLR7-mediated IFN-β production. Bropirimine is an orally bioactive immunomodulator with anti-cancer effect in transitional cell carcinoma in situ (CIS) of the bladder and upper urinary tract.

Physicochemical Properties

Molecular Formula	C10H8BRN3O
Molecular Weight	266.0940
Exact Mass	264.985
CAS #	56741-95-8
PubChem CID	135413497
Appearance	White to off-white solid powder
Density	1.7±0.1 g/cm3
Boiling Point	473.2±55.0 °C at 760 mmHg
Flash Point	240.0±31.5 °C
Vapour Pressure	0.0±1.2 mmHg at 25°C
Index of Refraction	1.696
LogP	1.9
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	2
Rotatable Bond Count	1
Heavy Atom Count	15
Complexity	343
Defined Atom Stereocenter Count	0
InChi Key	CIUUIPMOFZIWIZ-UHFFFAOYSA-N
InChi Code	InChI=1S/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
Chemical Name	2-amino-5-bromo-4-phenyl-1H-pyrimidin-6-one
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ADME/Pharmacokinetics	Metabolism / Metabolites Bropirimine has known human metabolites that include m-hydroxybropirimine and p-hydroxybropirimine.
References	[1]. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 2015;467(1):146‐151. [2]. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 1998;51(2):226‐231.
Additional Infomation	Bropirimine is a member of pyrimidines. Bropirimine is an oral immunostimulant that causes the body to produce interferon and other substances.

Solubility Data

Solubility (In Vitro)

DMSO : ~50 mg/mL (~187.91 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.08 mg/mL (7.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (7.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.7581 mL	18.7906 mL	37.5813 mL
	5 mM	0.7516 mL	3.7581 mL	7.5163 mL
	10 mM	0.3758 mL	1.8791 mL	3.7581 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.